Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Department of Pharmacology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
BMC Cancer. 2019 Jun 24;19(1):615. doi: 10.1186/s12885-019-5828-5.
A higher density of tumor-infiltrating lymphocytes (TILs) can lead to greater therapeutic effects and improved prognoses in cancer treatment. Similar results have been observed in breast cancer, particularly in triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2-enriched breast cancer. Calcium channel blockers (CCBs) are antihypertensive drugs (AHTs) that have also been reported to suppress the functions of T cells and macrophages. In this study, we evaluated TILs before pre-operative chemotherapy (POC) in breast cancer and retrospectively analyzed the correlation between CCBs and TILs or prognosis.
Of the patients treated with POC, 338 who had evaluable TILs were enrolled in this study. The correlations among TILs were evaluated according to standard methods, and CCB use and prognosis were investigated retrospectively.
Before POC, 65 patients (19.2%) took AHTs (CCBs: 41/338, 12.1%). The TIL density was significantly lower among patients administered CCBs for the group of all patients and for patients with TNBC (p = 0.040, p = 0.009, respectively). Additionally, patients with TNBC who were administered CCBs showed significantly lower response rates for POC (p = 0.040). In all patients receiving POC, no significant differences in disease-free survival (DFS) or overall survival (OS) were observed in patients administered CCBs (p = 0.712, p = 0.478, log-rank tests, respectively). Furthermore, no significant differences were found, even in patients with TNBC (DFS: p = 0.441, OS: p = 0.727, log-rank tests, respectively).
In patients with TNBC undergoing treatment for hypertension with CCBs, TILs in the needle biopsy specimens before treatment were significantly lower, and the response rate of POC was not sufficient. Thus, the immunosuppressive effects of CCBs may also affect the immune microenvironment.
肿瘤浸润淋巴细胞(TILs)密度较高可导致癌症治疗的疗效更好、预后更佳。在乳腺癌中也观察到了类似的结果,尤其是在三阴性乳腺癌(TNBC)和人表皮生长因子受体 2 富集型乳腺癌中。钙通道阻滞剂(CCBs)是降压药(AHTs),也有报道称其可抑制 T 细胞和巨噬细胞的功能。在本研究中,我们评估了乳腺癌患者术前化疗(POC)前的 TILs,并回顾性分析了 CCBs 与 TILs 或预后的相关性。
在接受 POC 治疗的患者中,纳入了 338 例可评估 TILs 的患者。根据标准方法评估 TILs 之间的相关性,并回顾性调查 CCB 使用与预后的关系。
在 POC 前,65 例患者(19.2%)服用 AHTs(CCBs:41/338,12.1%)。在所有患者和 TNBC 患者中,服用 CCBs 的患者 TIL 密度均显著较低(p=0.040,p=0.009)。此外,服用 CCBs 的 TNBC 患者对 POC 的反应率显著较低(p=0.040)。在所有接受 POC 的患者中,服用 CCBs 的患者在无病生存期(DFS)或总生存期(OS)方面均无显著差异(p=0.712,p=0.478,对数秩检验)。此外,在 TNBC 患者中也未发现差异(DFS:p=0.441,OS:p=0.727,对数秩检验)。
在接受 CCBs 治疗高血压的 TNBC 患者中,治疗前针吸活检标本中的 TILs 显著较低,POC 的反应率不足。因此,CCBs 的免疫抑制作用可能也会影响免疫微环境。